Navigation Links
Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/9/2009

CHADDS FORD, Pa., Jan. 9 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that David Holveck, President and Chief Executive Officer of Endo, will present a corporate update at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009 at 10:30 a.m. Pacific Time. The conference will be held January 12-15, 2009 in San Francisco.

A link to a live audio Webcast of the presentation may be accessed on the Endo Website at www.endo.com. The presentation will be archived for ninety days.

About Endo Pharmaceuticals

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ... for the year ended December 31, 2008. , "In ... said Dr. Brad Thompson, President and CEO of Oncolytics. ... by interim results reported in our US and UK ...
... Venture: QPTEDMONTON, March 4 /PRNewswire-FirstCall/ - Quest PharmaTech ... pharmaceutical company developing and commercializing products for the ... results from a study designed to investigate the ... (PDT) used in combination with immunotherapeutic agents in ...
... N.C., March 4 Micell Technologies announced today ... Micell Rapid Absorption Polymer DES System" during the ... on March 5, 2009. MiStent(TM), a Drug-Eluting Stent ... coating that delivers the potential benefits of the ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 2Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 3Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 4Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 5Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 6Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 7Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 8Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 9Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors 2Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors 3Micell Technologies' Rapid Absorption Polymer DES System to be Presented at CRT 2009 2
(Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into your ... the answer to your secret question. What,s your dog,s birthday? Who ... Labs , a digital infrastructure security company, launches the ... comes with usernames, passwords and PINs – 1U TM ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans for ... Funding for this $50 million capital project is part of ... summer. The medical education building will be ... complex, adjacent to 525@vine in Wake Forest Innovation Quarter. Construction ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... protein associated with Alzheimer's disease in the brain of ... between neuronal death and proteins previously associated with cancer. ... Feany, and colleagues from Brigham and Women's Hospital, Harvard ... the brain generally do not divide. It is therefore ...
... that tend and harvest gardens of fungus have ... their crops: antibiotic-producing bacteria that the insects harbor ... journal Science, an international team led by University ... and ancient nature of this mutualistic relationship. ...
... pollution is a serious and growing environmental problem, especially ... Georgia had, several years ago, used genetic techniques to ... sites. , There was a problem, however. The arsenic ... the plant, making it difficult to harvest for safe ...
Cached Biology News:Study reveals classic symbiotic relationship between ants, bacteria 2Study reveals classic symbiotic relationship between ants, bacteria 3Researchers discover way to transport environmental arsenic to plant leaves in new clean-up strategy 2
Polio component type I...
Procollagen type I C-terminal propeptide (human, PICP)...
Choriongonadotropin (human, hCG)...
... LC Sciences provides a comprehensive microarray ... regulatory/functional RNA embedded within non-coding RNAs ... and proprietary probe design, which enables ... of small RNAs (1). This comprehensive ...
Biology Products: